Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2030-01-31
Target enrollment:
Participant gender:
Summary
Clinical studies have shown that magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) of the prostate is safe and effective. In the TULSA procedure, prostate tissue is killed by heating with ultrasound. This clinical trial explores if adding drug therapy with Degarelix before TULSA has the potential to improve further the effectiveness of TULSA in the treatment of localized prostate cancer, especially for patients with more aggressive diseases.